PYRUKYND 5mg+20mg film-coated tablets medication leaflet

B06AX04 mitapivat • Blood and blood forming organs | Other hematological agents

Mitapivat is a medicine used in adults with haemolytic anaemia caused by pyruvate kinase deficiency, a rare inherited disorder in which red blood cells break down faster than normal. Treatment aims to raise haemoglobin and reduce symptoms related to anaemia.

The medicine activates pyruvate kinase in red blood cells, helping them produce energy and survive longer. It is not suitable for every type of anaemia. The diagnosis should be confirmed by tests recommended by a haematologist, including genetic or enzyme testing.

Mitapivat is taken by mouth, usually twice daily, with gradual dose adjustment based on response and tolerability. Do not stop it suddenly, because haemolysis and anaemia may worsen. If treatment has to be discontinued, your doctor will usually prescribe a stepwise dose reduction.

Side effects may include insomnia, nausea, back or joint pain, increased triglycerides, hot flushes, high blood pressure or hormone changes seen in blood tests. Tell your doctor about all other medicines you take, because some can change mitapivat levels and reduce effectiveness or increase side effects.

General data about PYRUKYND 5mg+20mg

Substance: mitapivat

Date of last drug list: 01-10-2025

Commercial code: W71336001

Concentration: 5mg+20mg

Pharmaceutical form: film-coated tablets

Quantity: 1

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ALMAC PHARMA SERVICES (IRELAND) LIMITED - IRLANDA DE NORD

Holder: AGIOS NETHERLANDS B.V. - OLANDA

Number: 1662/2022/03

Shelf life: 2 years

Concentrations available for mitapivat

20mg, 20mg+50mg, 50mg, 5mg, 5mg+20mg